Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

13.03.17	OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon (PR Newswire)
07.03.17	Regeneron and Sanofi to Present New Phase 3 Praluent® (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions (PR Newswire)
05.03.17	Regeneron, Sanofi: DUPIXENT Study In Atopic Dermatitis Shows Positive Data (RTTNews)
03.03.17	Sanofi Pasteur & AstraZeneca Join To Develop, Commercialize MEDI8897 (RTTNews)
27.02.17	Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Sanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses (PR Newswire)
27.02.17	Biotech Stocks Facing FDA Decision In March (RTTNews)
27.02.17	Sanofi, Lonza In Partnership To Build Swiss Biologics Production Facility (RTTNews)
09.02.17	AGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (RTTNews)
09.02.17	Sanofi Says Appeals Court Grants Stay Of Permanent Injunction For Praluent (RTTNews)
08.02.17	Appeals Court Grants Stay of Permanent Injunction for Praluent® (alirocumab) During Appeals Process (PR Newswire)
08.02.17	Sanofi Delivers 2016 Sales and Business EPS Growth at CER (PR Newswire)
08.02.17	Sanofi Stock Up As Q4 Profit More Than Doubles (RTTNews)
08.02.17	Sanofi - Interview du Directeur Général - Résultats 2016 (vidéo) (PR Newswire)
08.02.17	Sanofi CEO Interview - FY 2016 Results (video) (PR Newswire)
08.02.17	Sanofi CEO Interview - FY 2016 Results (video) (PR Newswire)
08.02.17	Sanofi Q4 Profit Up; Sees 2017 Business EPS To Be Stable To -3% At CER (RTTNews)
06.02.17	Research Reports Coverage on Drug Makers Stocks -- Sanofi, Impax Labs, Heron Therapeutics, and Biostar Pharma (PR Newswire)
02.02.17	Sanofi's Xyzal Now Available OTC, GLPG Kicks Off ALBATROSS, PRXL Opens Wallet (RTTNews)
01.02.17	Sanofi Appoints Hugo Fry as General Manager UK (PR Newswire)
01.02.17	Regeneron And Sanofi Say Canada Approves Kevzara (RTTNews)
01.02.17	Regeneron and Sanofi Announce First Approval of Kevzara™ (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients by Health Canada (PR Newswire)
31.01.17	Sanofi Pasteur Announces the Availability of Quadracel™ DTaP-IPV Vaccine for Children 4 Through 6 Years of Age in the U.S. (PR Newswire)
10.01.17	Amgen Issues Statement On Court Decision On Patent Litigation (RTTNews)
09.01.17	Sanofi and ImmuNext Enter into Agreement to Develop Treatments for Autoimmune Diseases (PR Newswire)
06.01.17	OTIC Hits Right Notes, GEMP To Report Data This Month, Busy Year Ahead For RVNC (RTTNews)
06.01.17	Regeneron, Sanofi To Appeal U.S. Court Rulings In Patent Litigation On Praluent (RTTNews)
04.01.17	Sanofi Says Soliqua 100/33 Now Available In U.S. (RTTNews)
03.01.17	Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Heron Therapeutics (PR Newswire)
02.01.17	Boehringer Ingelheim, Sanofi Successfully Close Business Swap On Jan. 1 (RTTNews)
29.12.16	U.S. FTC Requires Divestitures In $13.53 Bln Boehringer Ingelheim - Sanofi Deal (RTTNews)
22.12.16	Johnson & Johnson Resumes Talks With Actelion For Potential Takeover (RTTNews)
14.12.16	Sanofi Reportedly In Talks For Deal With Actelion (RTTNews)
13.12.16	Scottish Medicines Consortium Okays Sanofi Prostate Cancer Drug (RTTNews)
12.12.16	Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug (PR Newswire)
12.12.16	Scottish Medicines Consortium Approves Sanofi Prostate Cancer Drug (PR Newswire)
08.12.16	NWBO To Leave Nasdaq, Voyager Cruises Ahead, Watch Out For REGN (RTTNews)
08.12.16	Regeneron, Sanofi: EMA Accepts Dupixent Marketing Application For Review (RTTNews)
08.12.16	Regeneron and Sanofi Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA (PR Newswire)
06.12.16	Bloomberg : Sanofi To Explore Counterbid For Actelion Amid J&J Talks (RTTNews)
28.11.16	Drug Makers Stocks on Investors' Radar -- Immune Pharma, Sanofi, Biostar Pharma, and Shire (PR Newswire)
22.11.16	ACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmab's Old Drug (RTTNews)
22.11.16	Sanofi Gets FDA Approval Of Soliqua 100/33 To Treat Adults With Type 2 Diabetes (RTTNews)
22.11.16	Sanofi Receives FDA Approval of Soliqua™ 100/33 for the Treatment of Adults with Type 2 Diabetes (PR Newswire)
18.11.16	Global Survey into Perceptions of Men’s Health Reveals British Men Are Not Reaping Benefits of Local Health Services and Information (PR Newswire)
18.11.16	BSTC Finds New Use For Old Drug, FHCO Gets A Boost, SUPN Put On Notice (RTTNews)
14.11.16	Alnylam : Sanofi Genzyme Opt-in Decision For Co-Commercialization Of Fitusiran (RTTNews)
11.11.16	Sanofi Reports CHMP Recommendation For Suliqua - Quick Facts (RTTNews)
10.11.16	MannKind And Sanofi Enter Into Agreement On AFREZZ (RTTNews)
31.10.16	BIIB To Face FDA, It's A Thumb Down For REGN, STJ Meets Trial Goal (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

20.12.24		Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer
17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung

20.12.24

Wechsel bei Sanofi: Ex-Morphosys-Chef Kress tritt in den Verwaltungsrat ein -Sanofi-Aktie tiefer

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert